- NHL Treatment
- Hodgkin's Treatment
- Clinical Trials
- Monoclonal Antibodies
- Types of NHL
Lymphoma and Pets
FDA Puts Black Box Warning on Two Drugs
The U.S. Food and Drug Administration last week indicated that it has strengthened the warnings on a pair of blood cancer drugs because of an increased problem with hepatitis B reactivation.
The drugs in question are:
- Arzerra: FDA approved in 2009 for the treatment of chronic lymphocytic leukemia (CLL).
- Rituxan: FDA approved in 1999, and currently an approved treatment for CLL and non-Hodgkin's follicular lymphoma, among other diseases.
Heightened risk of hepatitis B
The FDA will add a black box warning to the drugs, illuminating the already-known risk that these drugs can cause reactivation of the hepatitis B virus in any person previously infected with it. Despite the fact that the warning is included in the label, patients with a history of hepatitis infection are being given the drug and some have died on account of it.
Doctors are being strongly urged to screen all patients for hepatitis B infection prior to administering or prescribing either drug, as both will suppress the immune system and make the body vulnerable to reactivation, illness and possibly death.